Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies.

Safdar, Aqsa; Butt, Muhammad Hammad; Ahmad, Abrar; Zaman, Muhammad

Safdar, Aqsa; Butt, Muhammad Hammad; Ahmad, Abrar; Zaman, Muhammad.

Afiliação

Safdar A; Faculty of Pharmacy, 66901University of Central Punjab, Lahore, Pakistan.
Butt MH; Faculty of Pharmacy, 66901University of Central Punjab, Lahore, Pakistan.
Ahmad A; Faculty of Pharmacy, 66901University of Central Punjab, Lahore, Pakistan.
Zaman M; Faculty of Pharmacy, 66901University of Central Punjab, Lahore, Pakistan.

J Oncol Pharm Pract ; 27(5): 1195-1204, 2021 Jul.

Article em En | MEDLINE | ID: mdl-34096401

Assuntos

Anticorpos Monoclonais/uso terapêutico; Medicamentos Biossimilares/uso terapêutico; Humanos; Oncologia

Palavras-chave

Biosimilars; bevacizumab; oncology practice; pegfilgrastim; rituximab; trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares / Anticorpos Monoclonais Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google